MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It operates through Beauty, Pharma, and Real Estate segments. The company offers medical-aesthetic beauty surgeries and treatments, as well as operation and provision of medical infrastructures for partner companies; and sells pharmaceuticals and medical products in the areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. It also provides plastic and aesthetic treatments and surgeries; and operates European mail-order pharmacy. In addition, the company is involved in real estate business; acts as an investment manager; renewable energies; and project development, including new residential construction/owner occupied homes. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. MPH Health Care AG was incorporated in 2008 and is based in Berlin, Germany.…
EQS-News: MPH Health Care AG platziert erfolgreich 927.755 Aktien der M1 Kliniken AG zu 17,50 Euro je Aktie und erzielt einen Bruttoerlös von rund 16 Millionen Euro
MPH Health Care (ETR: 93M1) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Asset Management industry, part of the Financial Services sector, and reports about 2 employees.
The shares were at 31.00 EUR on 20 November 2026, up 107.2% over 52 weeks. Its 52-week range is 17.70 EUR to 34.40 EUR: the price is 9.9% below the high and 75.1% above the low.
At a market capitalisation of 132.72M EUR, it trades at 2.8 times trailing earnings. The median trailing P/E of its 18 largest Asset Management peers is 14.8, a discount of 81% for 93M1. It pays a dividend yielding 14.62% (it pays out 11% of its earnings), against a median of 1.81% among the dividend payers in that peer group.
MPH Health Care reports return on equity of -12.0%, an operating margin of 97.3% and revenue up 9.5% year over year.
Its debt exceeds its cash by 12.55M EUR, a debt-to-equity ratio of 0.05. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 40.00 EUR is 29.0% above the current price.
No upcoming events tracked.